Non-invasive molecular imaging for preclinical cancer therapeutic development

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 719-735

  O'Farrell, A C ^a,d   Shnyder, S D ^a   Marston, G ^b   Coletta, P L ^b   Gill, J H ^a,c  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c DURHAM UNIVERSITY   (United Kingdom)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

bioluminescence; cancer pharmacology; MRI; non invasive imaging; PET; ultrasound

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; BEVACIZUMAB; CONTRAST MEDIUM; DOXORUBICIN; ENZASTAURIN; ERLOTINIB; GADOLINIUM; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; LAPATINIB; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; OMBRABULIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; QUANTUM DOT; TRASTUZUMAB; VATALANIB; VORINOSTAT;

BIOLUMINESCENCE IMAGING; BREAST CANCER; CANCER MODEL; CANCER THERAPY; CONTRAST ENHANCEMENT; CUTANEOUS T CELL LYMPHOMA; DOPPLER FLOWMETRY; DRUG SCREENING; FLUORESCENCE IMAGING; GLIOBLASTOMA; HEAD AND NECK CANCER; HIGH FREQUENCY ULTRASOUND; HUMAN; KIDNEY CANCER; LUNG CARCINOMA; METASTASIS; MICRO-COMPUTED TOMOGRAPHY; MICROBUBBLE; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY TUMOR; PANCREAS TUMOR; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUICIDE GENE THERAPY; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; TUMOR BURDEN; WHOLE BODY IMAGING;

EID: 84878338992     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12155     Document Type: Review

References (161)

1. Abdelrahman MA, Marston G, Hull MA, Markham AF, Jones PF, Evans JA, et al. (2012). High-frequency ultrasound for in vivo measurement of colon wall thickness in mice. Ultrasound Med Biol 38: 432-442.
2. Ahlgren S, Wallberg H, Tran TA, Widstrom C, Hjertman M, Abrahmsen L, et al. (2009). Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 50: 781-789.
3. Ali MM, Janic B, Babajani-Feremi A, Varma NR, Iskander AS, Anagli J, et al. (2010). Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One 5: e8727.
4. Amoh Y, Nagakura C, Maitra A, Moossa AR, Katsuoka K, Hoffman RM, et al. (2006). Dual-color imaging of nascent angiogenesis and its inhibition in liver metastases of pancreatic cancer. Anticancer Res 26: 3237-3242.
5. Angst E, Chen M, Mojadidi M, Hines OJ, Reber HA, Eibl G, (2010). Bioluminescence imaging of angiogenesis in a murine orthotopic pancreatic cancer model. Mol Imaging Biol 12: 570-575.
6. Avril N, Propper D, (2007). Functional PET imaging in cancer drug development. Future Oncol 3: 215-228.
7. Ayers GD, McKinley ET, Zhao P, Fritz JM, Metry RE, Deal BC, et al. (2010). Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med 29: 891-901.
8. Bao A, Phillips WT, Goins B, Zheng X, Sabour S, Natarajan M, et al. (2006). Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection. Int J Pharm 316: 162-169.
9. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J, (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831.
10. Bentolila LA, Ebenstein Y, Weiss S, (2009). Quantum dots for in vivo small-animal imaging. J Nucl Med 50: 493-496.
11. Bhaumik S, Lewis XZ, Gambhir SS, (2004). Optical imaging of Renilla luciferase, synthetic Renilla luciferase, and firefly luciferase reporter gene expression in living mice. J Biomed Opt 9: 578-586.
12. Breton E, Goetz C, Kintz J, Accart N, Aubertin G, Grellier B, et al. (2010). In vivo preclinical low-field MRI monitoring of tumor growth following a suicide-gene therapy in an orthotopic mice model of human glioblastoma. C R Biol 333: 220-225.
13. Brix G, Griebel J, Kiessling F, Wenz F, (2010). Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nuc Med Mol Imag 37 (Suppl. 1): S30-S51.
14. Cai W, Rao J, Gambhir SS, Chen X, (2006). How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 5: 2624-2633.
15. Cejka D, Kuntner C, Preusser M, Fritzer-Szekeres M, Fueger BJ, Strommer S, et al. (2009). FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. Br J Cancer 100: 1739-1745.
16. Chang CH, Hsu WC, Wang CY, Jan ML, Tsai TH, Lee TW, et al. (2007). Longitudinal microSPECT/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats. Anticancer Res 27: 3251-3258.
17. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. (2007). Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25: 4714-4721.
18. Cheung AM, Brown AS, Hastie LA, Cucevic V, Roy M, Lacefield JC, et al. (2005). Three-dimensional ultrasound biomicroscopy for xenograft growth analysis. Ultrasound Med Biol 31: 865-870.
19. Choi HS, Liu W, Liu F, Nasr K, Misra P, Bawendi MG, et al. (2010). Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 5: 42-47.
20. Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F, (2010). Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release 144: 324-331.
21. Contag CH, Ross BD, (2002). It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging 16: 378-387.
22. Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A, Lawrence TS, (2010). Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res 16: 3205-3214.
23. Cordero AB, Kwon Y, Hua X, Godwin AK, (2010). In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. J Vis Exp 42: 2125.
24. Czernin J, Weber WA, Herschman HR, (2006). Molecular imaging in the development of cancer therapeutics. Annu Rev Med 57: 99-118.
25. van Dalen JA, Vogel WV, Corstens FH, Oyen WJ, (2007). Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations. Cancer Imaging 7: 77-83.
26. Davis SC, Samkoe KS, O'Hara JA, Gibbs-Strauss SL, Payne HL, Hoopes PJ, et al. (2010). MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. Acad Radiol 17: 271-276.
27. Deroose CM, De A, Loening AM, Chow PL, Ray P, Chatziioannou AF, et al. (2007). Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J Nucl Med 48: 295-303.
28. Deshpande N, Ren Y, Foygel K, Rosenberg J, Willmann JK, (2011). Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. Radiology 258: 804-811.
29. Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, et al. (2010). Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 10: 188.
30. Dickson PV, Hamner B, Ng CY, Hall MM, Zhou J, Hargrove PW, et al. (2007). In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg 42: 1172-1179.
31. Drake JM, Danke JR, Henry MD, (2010). Bone-specific growth inhibition of prostate cancer metastasis by atrasentan. Cancer Biol Ther 9: 607-614.
32. Dunphy MP, Entenberg D, Toledo-Crow R, Larson SM, (2009). In vivo microcartography and subcellular imaging of tumor angiogenesis: a novel platform for translational angiogenesis research. Microvasc Res 78: 51-56.
33. Durkee BY, Mudd SR, Roen CN, Clipson L, Newton MA, Weichert JP, et al. (2008). Reproducibility of tumor volume measurement at microCT colonography in living mice. Acad Radiol 15: 334-341.
34. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
35. Fomchenko EI, Holland EC, (2006). Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12: 5288-5297.
36. Foster FS, Zhang MY, Zhou YQ, Liu G, Mehi J, Cherin E, et al. (2002). A new ultrasound instrument for in vivo microimaging of mice. Ultrasound Med Biol 28: 1165-1172.
37. Fushiki H, Kanoh-Azuma T, Katoh M, Kawabata K, Jiang J, Tsuchiya N, et al. (2009). Quantification of mouse pulmonary cancer models by microcomputed tomography imaging. Cancer Sci 100: 1544-1549.
38. Garcia Garayoa E, Schweinsberg C, Maes V, Ruegg D, Blanc A, Blauenstein P, et al. (2007). New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. Q J Nucl Med Mol Imaging 51: 42-50.
39. Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS, (2002). High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62: 6371-6375.
40. Gould SJ, Subramani S, (1988). Firefly luciferase as a tool in molecular and cell biology. Anal Biochem 175: 5-13.
41. Graham KC, Wirtzfeld LA, MacKenzie LT, Postenka CO, Groom AC, MacDonald IC, et al. (2005). Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models. Cancer Res 65: 5231-5237.
42. Grange C, Geninatti-Crich S, Esposito G, Alberti D, Tei L, Bussolati B, et al. (2010). Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. Cancer Res 70: 2180-2190.
43. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC, (1999). In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81: 1318-1327.
44. Grozio A, Paleari L, Catassi A, Servent D, Cilli M, Piccardi F, et al. (2008). Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development. Int J Cancer 122: 1911-1915.
45. Guibal A, Taillade L, Mule S, Comperat E, Badachi Y, Golmard JL, et al. (2010). Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Radiology 254: 420-429.
46. Gwyther SJ, Schwartz LH, (2008). How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer 44: 39-45.
47. Hasegawa S, Furukawa T, Saga T, (2010). Molecular MR imaging of cancer gene therapy: ferritin transgene reporter takes the stage. Magn Reson Med Sci 9: 37-47.
48. Hawcroft G, Volpato M, Marston G, Ingram N, Perry SL, Cockbain AJ, et al. (2012). The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility. Br J Pharmacol 166: 1724-1737.
49. Hawes JJ, Reilly KM, (2010). Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis. Toxicol Pathol 38: 123-130.
50. Hoffman RM, (2009). Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clini Exp Metas 26: 345-355.
51. Holzmuller R, Mantwill K, Haczek C, Rognoni E, Anton M, Kasajima A, et al. (2011). YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int J Cancer 129: 1265-1276.
52. Horowitz ME, Etcubanas E, Christensen ML, Houghton JA, George SL, Green AA, et al. (1988). Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 6: 308-314.
53. Hoyt K, Warram JM, Umphrey H, Belt L, Lockhart ME, Robbin ML, et al. (2010). Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med 29: 577-585.
54. Huynh AS, Abrahams DF, Torres MS, Baldwin MK, Gillies RJ, Morse DL, (2011). Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One 6: e20330.
55. Hwang do W, Ko HY, Kim SK, Kim D, Lee DS, Kim S, (2009). Development of a quadruple imaging modality by using nanoparticles. Chemistry 15: 9387-9393.
56. Jain KK, (2011). Advances in the field of nanooncology. BMC Med 8: 83.
57. Jaiswal RS, Singh J, Adams GP, (2009). High-resolution ultrasound biomicroscopy for monitoring ovarian structures in mice. Reprod Biol Endocrinol 7: 69.
58. Jeon YH, Bae SA, Lee YJ, Lee YL, Lee SW, Yoon GS, et al. (2010). Evaluation of the reversal of multidrug resistance by MDR1 ribonucleic acid interference in a human colon cancer model using a Renilla luciferase reporter gene and coelenterazine. Mol Imaging 9: 343-350.
59. Jia D, Koonce NA, Halakatti R, Li X, Yaccoby S, Swain FL, et al. (2010). Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent. Radiat Res 173: 809-817.
60. Jolly C, Jeanny JC, Behar-Cohen F, Laugier P, Saied A, (2005). High-resolution ultrasonography of subretinal structure and assessment of retina degeneration in rat. Exp Eye Res 81: 592-601.
61. Jones LR, Goun EA, Shinde R, Rothbard JB, Contag CH, Wender PA, (2006). Releasable luciferin-transporter conjugates: tools for the real-time analysis of cellular uptake and release. J Am Chem Soc 128: 6526-6527.
62. de Jong M, Maina T, (2010). Of mice and humans: are they the same?-Implications in cancer translational research. J Nucl Med 51: 501-504.
63. Jurczok A, Fornara P, Soling A, (2008). Bioluminescence imaging to monitor bladder cancer cell adhesion in vivo: a new approach to optimize a syngeneic, orthotopic, murine bladder cancer model. BJU Int 101: 120-124.
64. Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, et al. (2010). Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res 16: 4779-4788.
65. Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, et al. (2006). Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 66: 11991-11997.
66. Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Xu J, Jones L, et al. (2007). Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 6: 48.
67. Kassouf W, Brown GA, Shetty A, Hazle JD, Stafford RJ, Rosser CJ, et al. (2007). An in vivo orthotopic canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy and drug delivery for prostate cancer. Urology 70: 822-825.
68. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al. (2003). Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Can Res 9: 3578-3588.
69. Kemper EM, Leenders W, Kusters B, Lyons S, Buckle T, Heerschap A, et al. (2006). Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. Eur J Cancer 42: 3294-3303.
70. Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, et al. (2008). Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 68: 8369-8376.
71. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, et al. (2007). Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67: 9337-9345.
72. Kramer-Marek G, Kiesewetter DO, Capala J, (2009). Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 50: 1131-1139.
73. Krug LM, Milton DT, Jungbluth AA, Chen LC, Quaia E, Pandit-Taskar N, et al. (2007). Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. J Thorac Oncol 2: 947-952.
74. Laforest R, Liu X, (2008). Image quality with non-standard nuclides in positron emission tomography. Q J Nucl Med Mol Imaging 52: 151-158.
75. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, et al. (2002). Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA 99: 16551-16555.
76. Lee JS, Orita H, Gabrielson K, Alvey S, Hagemann RL, Kuhajda FP, et al. (2007a). FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer. Pharm Res 24: 1202-1207.
77. Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD, Rehemtulla A, (2007b). Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res 13: 1839-1846.
78. Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, et al. (2006). In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Cancer Res 66: 7621-7629.
79. Li C, Penet MF, Winnard P Jr, Artemov D, Bhujwalla ZM, (2008). Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res 14: 515-522.
80. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, et al. (2007). Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67: 7525-7533.
81. Lim E, Modi KD, Kim J, (2009). In vivo bioluminescent imaging of mammary tumors using IVIS spectrum. J Vis Exp 26: 1210.
82. Liu T, Ding Y, Xie W, Li Z, Bai X, Li X, et al. (2007). An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res 13: 3960-3967.
83. Loo WT, Sasano H, Chow LW, (2007). Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues. Biomed Pharmacother 61: 596-600.
84. Lyons SK, (2005). Advances in imaging mouse tumour models in vivo. J Pathol 205: 194-205.
85. McCann CM, Waterman P, Figueiredo JL, Aikawa E, Weissleder R, Chen JW, (2009). Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy. NeuroImage 45: 360-369.
86. McNally LR, Welch DR, Beck BH, Stafford LJ, Long JW, Sellers JC, et al. (2010). KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clin Exp Metastasis 27: 591-600.
87. Marks PA, Breslow R, (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90.
88. Massoud TF, Gambhir SS, (2003). Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17: 545-580.
89. Massoud TF, Gambhir SS, (2007). Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends Mol Med 13: 183-191.
90. Medarova Z, Rashkovetsky L, Pantazopoulos P, Moore A, (2009). Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 69: 1182-1189.
91. Mendoza-Sanchez AN, Ferro-Flores G, Ocampo-Garcia BE, Morales-Avila E, de M Ramírez F, De Leon-Rodriguez LM, et al. (2011). Lys3-bombesin conjugated to 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging. J Biomed Nanotechnol 6: 375-384.
92. Moran CM, Pye SD, Ellis W, Janeczko A, Morris KD, McNeilly AS, et al. (2011). A comparison of the imaging performance of high resolution ultrasound scanners for preclinical imaging. Ultrasound Med Biol 37: 493-501.
93. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E, (2008). RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68: 861-871.
94. Moriyama EH, Niedre MJ, Jarvi MT, Mocanu JD, Moriyama Y, Subarsky P, et al. (2008). The influence of hypoxia on bioluminescence in luciferase- transfected gliosarcoma tumor cells in vitro. Photochem Photobiol Sci 7: 675-680.
95. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, et al. (2007). Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med 58: 270-280.
96. Mouchess ML, Sohara Y, Nelson MD Jr, DeCLerck YA, Moats RA, (2006). Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model. J Comput Assist Tomogr 30: 525-534.
97. Mulder WJ, Castermans K, van Beijnum JR, Oude Egbrink MG, Chin PT, Fayad ZA, et al. (2009). Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis 12: 17-24.
98. Nam T, Park S, Lee SY, Park K, Choi K, Song IC, et al. (2010). Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. Bioconjug Chem 21: 578-582.
99. Nie S, Xing Y, Kim GJ, Simons JW, (2007). Nanotechnology applications in cancer. Annu Rev Biomed Eng 9: 257-288.
100. Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, et al. (2005). Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217: 243-253.
101. O'Connor JP, Jackson A, Parker GJ, Jayson GC, (2007). DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96: 189-195.
102. Ohta S, Lai EW, Morris JC, Bakan DA, Klaunberg B, Cleary S, et al. (2006). MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. Int J Cancer 119: 2236-2241.
103. Olive KP, Tuveson DA, (2006). The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 12: 5277-5287.
104. Otsuka H, Morita N, Yamashita K, Nishitani H, (2007). FDG-PET/CT for cancer management. J Med Invest 54: 195-199.
105. Ozawa T, James CD, (2010). Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp 41: 1986.
106. Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, Johnson DK, (2000). High resolution X-ray computed tomography: an emerging tool for small animal cancer research. Neoplasia 2: 62-70.
107. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, et al. (2010). Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 16: 5458-5468.
108. Pollok KE, Lahn M, Enas N, McNulty A, Graff J, Cai S, et al. (2009). In vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography. J Oncol 2009: 596560.
109. Prajapati SI, Keller C, (2011). Contrast enhanced vessel imaging using microCT. J Vis Exp 47: 2377.
110. Proschek D, Mack MG, Kurth AA, Proschek P, Martin B, Hansmann ML, et al. (2008). Radiofrequency ablation of experimental bone metastases in nude rats. Anticancer Res 28: 879-885.
111. Rad AM, Iskander AS, Janic B, Knight RA, Arbab AS, Soltanian-Zadeh H, (2009). AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models: a preliminary study. BMC Biotech 9: 28.
112. Rahmim A, Zaidi H, (2008). PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 29: 193-207.
113. Rittenhouse-Olson K, (2007). Jaa-f11: extending the life of mice with breast cancer. Expert Opin Biol Ther 7: 923-928.
114. Rousseau J, Escriou V, Perrot P, Picarda G, Charrier C, Scherman D, et al. (2010). Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther 17: 387-397.
115. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, et al. (2007). Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73: 1318-1329.
116. Sattler UG, Meyer SS, Quennet V, Hoerner C, Knoerzer H, Fabian C, et al. (2010). Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol 94: 102-109.
117. Savla R, Taratula O, Garbuzenko O, Minko T, (2011). Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release 153: 16-22.
118. Scabini M, Stellari F, Cappella P, Rizzitano S, Texido G, Pesenti E, (2011). In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation. Apoptosis 16: 198-207.
119. Schambach SJ, Bag S, Schilling L, Groden C, Brockmann MA, (2010). Application of micro-CT in small animal imaging. Methods 50: 2-13.
120. Schroder L, Lowery TJ, Hilty C, Wemmer DE, Pines A, (2006). Molecular imaging using a targeted magnetic resonance hyperpolarized biosensor. Science 314: 446-449.
121. Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, et al. (2010). Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 9: 2057-2067.
122. Shelton LM, Huysentruyt LC, Seyfried TN, (2010). Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int J Cancer 127: 2478-2485.
123. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, et al. (2010). Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28: 585-593.
124. Snoeks TJ, Lowik CW, Kaijzel EL, (2010). 'In vivo' optical approaches to angiogenesis imaging. Angiogenesis 13: 135-147.
125. Strijkers GJ, Kluza E, Van Tilborg GA, van der Schaft DW, Griffioen AW, Mulder WJ, et al. (2010). Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis 13: 161-173.
126. Suggitt M, Bibby MC, (2005). 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11: 971-981.
127. Sun A, Hou L, Prugpichailers T, Dunkel J, Kalani MA, Chen X, et al. (2010a). Firefly luciferase-based dynamic bioluminescence imaging: a noninvasive technique to assess tumor angiogenesis. Neurosurgery 66: 751-757.
128. Sun D, Yang K, Zheng G, Li Z, Cao Y, (2010b). Study on effect of peptide-conjugated near-infrared fluorescent quantum dots on the clone formation, proliferation, apoptosis, and tumorigenicity ability of human buccal squamous cell carcinoma cell line BcaCD885. Int J Nanomedicine 5: 401-405.
129. Sun J, Zhu MQ, Fu K, Lewinski N, Drezek RA, (2007). Lead sulfide near-infrared quantum dot bioconjugates for targeted molecular imaging. Int J Nanomedicine 2: 235-240.
130. Sun L, Xu X, Richard WD, Feng C, Johnson JA, Shung KK, (2008). A high-frame rate duplex ultrasound biomicroscopy for small animal imaging in vivo. IEEE Trans Biomed Eng 55: 2039-2049.
131. Takahashi A, Ohkohchi N, Yasunaga M, Kuroda J, Koga Y, Kenmotsu H, et al. (2010). Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases. Clin Cancer Res 16: 4822-4831.
132. Taniguchi Y, Kawano K, Minowa T, Sugino T, Shimojo Y, Maitani Y, (2010). Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-beta type I receptor inhibitor. Cancer Sci 10: 2207-2213.
133. Tavares AJ, Chong L, Petryayeva E, Algar WR, Krull UJ, (2011). Quantum dots as contrast agents for in vivo tumor imaging: progress and issues. Anal Bioanal Chem 399: 2331-2342.
134. Tehranipour N, AL-Nahhas A, Canelo R, Stamp G, Woo K, Tait P, et al. (2007). Concordant F-18 FDG PET and Y-90 bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology. Clin Nuc Med 32: 371-374.
135. Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J, (2010). Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer 9: 299.
136. Torigian DA, Huang SS, Houseni M, Alavi A, (2007). Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 57: 206-224.
137. Troy T, Jekic-McMullen D, Sambucetti L, Rice B, (2004). Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging 3: 9-23.
138. Tung CH, (2004). Fluorescent peptide probes for in vivo diagnostic imaging. Biopolymers 76: 391-403.
139. Turnbull DH, Starkoski BG, Harasiewicz KA, Semple JL, From L, Gupta AK, et al. (1995). A 40-100 MHz B-scan ultrasound backscatter microscope for skin imaging. Ultrasound Med Biol 21: 79-88.
140. Vansteenkiste JF, (2002). Imaging in lung cancer: positron emission tomography scan. Eur Resp Journal 35: 49s-60s.
141. Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, et al. (2010). Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. Clin Cancer Res 16: 4434-4445.
142. Vikis HG, Jackson EN, Krupnick AS, Franklin A, Gelman AE, Chen Q, et al. (2010). Strain-specific susceptibility for pulmonary metastasis of sarcoma 180 cells in inbred mice. Cancer Res 70: 4859-4867.
143. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
144. Walter MA, Hildebrandt IJ, Hacke K, Kesner AL, Kelly O, Lawson GW, et al. (2010). Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice. J Nucl Med 51: 1285-1292.
145. Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, et al. (2010). TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 16: 2591-2604.
146. Watkins GA, Jones EF, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, et al. (2009). Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Biorg Med Chem 17: 653-659.
147. Weisheng Z, Min C, West DB, Purchio AF, (2005). Visualizing drug efficacy in vivo. Mol Imaging 4: 88-90.
148. Weiss MS, Penalver Bernabe B, Bellis AD, Broadbelt LJ, Jeruss JS, Shea LD, (2010). Dynamic, large-scale profiling of transcription factor activity from live cells in 3D culture. PLoS One 5: e14026.
149. Weissleder R, Pittet MJ, (2008). Imaging in the era of molecular oncology. Nature 452: 580-589.
150. Wender PA, Goun EA, Jones LR, Pillow TH, Rothbard JB, Shinde R, et al. (2007). Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice. Proc Natl Acad Sci USA 104: 10340-10345.
151. Wessels JT, Busse AC, Mahrt J, Dullin C, Grabbe E, Mueller GA, (2007). In vivo imaging in experimental preclinical tumor research-a review. Cytometry A 71: 542-549.
152. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. (2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
153. Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, et al. (2010). PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 31: 3016-3022.
154. Xuan JW, Bygrave M, Jiang H, Valiyeva F, Dunmore-Buyze J, Holdsworth DW, et al. (2007). Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound. Cancer Res 67: 2830-2839.
155. Zaidi H, Prasad R, (2009). Advances in multimodality molecular imaging. J Med Phys 34: 122-128.
156. Zehnder-Fjallman AH, Marty C, Halin C, Hohn A, Schibli R, Ballmer-Hofer K, et al. (2007). Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis. Oncol Rep 18: 933-941.
157. Zeng Q, Yang Z, Gao YJ, Yuan H, Cui K, Shi Y, et al. (2010). Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. Eur J Cancer 46: 1132-1143.
158. Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, et al. (2010). PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res 16: 5177-5188.
159. Zhang GJ, Chen TB, Bednar B, Connolly BM, Hargreaves R, Sur C, et al. (2007). Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation. Neoplasia 9: 652-661.
160. Zhao D, Richer E, Antich PP, Mason RP, (2008). Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI. FASEB J 22: 2445-2451.
161. Zhao YZ, Lu CT, Zhou ZC, Jin Z, Zhang L, Sun CZ, et al. (2010). Enhancing chemotherapeutic drug inhibition on tumor growth by ultrasound: an in vivo experiment. J Drug Target 19: 154-160.